Procurement of Sotatercept (Winrevair)

This tender is for the procurement of Sotatercept, marketed as Winrevair. This medication is indicated for the treatment of pulmonary arterial hypertension (PAH) in adult patients classified under WHO functional class II, III, or IV, when used in combination with other PAH therapies. Sotatercept functions as an activin signaling inhibitor. It selectively binds to activin A, a dimeric glycoprotein belonging to the transforming growth factor beta (TGF-beta) superfamily. By binding to the activin type IIA receptor (ActRIIA), activin A modulates signaling pathways crucial for inflammation, cell proliferation, apoptosis, and tissue homeostasis. The molecule's mechanism of action involves inhibiting activin signaling, which is believed to be a key pathway in the pathogenesis of pulmonary hypertension. The estimated value of this procurement is approximately €500,000, calculated based on the list price with 0% VAT. This acquisition aims to provide a novel therapeutic option for patients suffering from PAH, addressing a significant unmet medical need in cardiovascular medicine. The tender details will outline the specific supply and delivery requirements for this high-value pharmaceutical product.

This is a supplies contract in the health and medical services sector, with a focus on Pharmaceuticals. Located in Finland, Europe, this opportunity is open to firms and consortiums.

Published through TED - Tenders Electronic Daily (EU), a national government procurement portal. Public procurement tenders follow the country's national bidding regulations and may have specific eligibility and documentation requirements for the supply of goods in the health and medical services sector. Supply contracts typically require bidders to demonstrate product compliance with technical specifications, delivery capacity, and relevant certifications. This contract has already been awarded. The information is published for transparency and market intelligence purposes.